Keryx gains on GSK takeout chatter

Keryx Biopharmaceuticals Inc. (NASDAQ:KERX) gained $0.76 (12%) to $7.19 on Friday after media reports said that GlaxoSmithKline plc (LSE:GSK; NYSE:GSK) is considering acquiring the biotech. Keryx's Friday stock move translates to a $61.9 million gain in market cap for a closing valuation of $585.2 million. GSK declined to comment on the rumors, while Keryx could not be reached. ...